Forecast Insight - Osteoarthritis - The COX-2 pipeline collapses - a new market research report


With several recent non-approvable decisions in the osteoarthritis market since 2006, Datamonitor has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of
nearly $5.5 billion in 2017.


This report gives a strategic analysis of the likely impact that recent events will have on the osteoarthritis market Includes osteoarthritis-specific and total brand sales forecasts for the key brands in the seven major markets to 2017 This report provides a global market snapshot by including osteoarthritis-specific sales analysis for leading brands outside the seven major markets This report includes updated forecasts of nearly 130 currently marketed products and reassesses pipeline product launch dates and sales forecasts


After three years of decline, market sales grew by 0.8% (2006-07) to reach $4 billion in the 7MM in 2007. Driving growth was an increase in sales of COX-2, non-narcotic analgesic and corticosteroid classes. Market sales will reach $5.5 billion by 2017 (3.2% CAGR) boosted by pipeline product launches, particularly NicOx´s naproxcinod. Lessened side effect concern and clever marketing contributed to the rebound in Celebrex sales. Also contributing to Celebrex´s reprise was the Japanese launch in June 2007. Celebrex will remain the market leading brand for osteoarthritis treatment until patent expiry in 2014, when more than 70% first year generic erosion is forecast. Arcoxia (etoricoxib) and Prexige (lumiracoxib) will not launch in the US as previously predicted. The COX-2 pipeline has collapsed with little sign of future promise. This counters the rise in Celebrex and Arcoxia sales, which show that opportunities exist, but at present regulatory requirement generates a large barrier to entry.

Reasons to Purchase

Quantify the current size of the seven major markets and the trends in the rest of the world Understand when late-stage pipeline products will launch and what impact this will have on the market during the forecast period 2007 to 2017 Assess the impact of events, such as patent expiries, on the osteoarthritis-specific sales of key brand name products.

Mike King

Forecast Insight - Osteoarthritis - The COX-2 pipeline collapses (Datamonitor)
Market: Healthcare and Medical
Published Date: 23/05/2008
Market Research Report Title: Forecast Insight - Osteoarthritis - The COX-2 pipeline collapses
Report Type: Market Report
Country: Global
Number of Pages: 71

Etude complète disponible à l'achat (8.000 £ !)
Source : Forecast Insight via Live-PR

Aucun commentaire: